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Leukocytes, inflammation, and cardiovascular diseases 
Leukocytes have occupied center stage as protagonists in host defenses and 
inflammatory diseases since the era of the 19th century pioneers including 
Virchow, Cohnheim, and Metchnikoff.1 These investigators helped establish the 
scientific basis of modern medicine through their careful morphologic observation, 
experimental manipulations, and deductive reasoning. The romance of the white 
corpuscle achieved popular culture status in the beginning of the 20th century, as 
reflected by George Bernard Shaw’s exhortation to “stimulate the phagocytes” in 
his 1906 play “The Doctor’s Dilemma.” 2 
Application of the tools of biochemistry and cell biology enabled fleshing 
out the functions of phagocytes in the 20th century. Such studies discovered the 
ability of leukocytes to produce reactive oxygen species (ROS), lipid mediators, 
and cytokines, as well as granular constituents including plentiful proteinases.   
This potent armamentarium equips leukocytes to fight invaders, or when turned 
against the host, to produce or promote disease. 
The field of leukocyte biology has flourished during the last several decades. 
We now possess detailed knowledge of the way in which various leukocyte sub-
classes enter, tarry within, and exit the vasculature and tissue compartments 
(Figure). We have learned what signals beckon these cells to extravasate, and 
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delineated detailed mechanisms by which they do so. Leukocytes not only enter 
tissues, but persist within them in response to specific signals, and may in some 
cases emmigrate, each step subject to regulation by various interesting mechanisms 
and paths. 
The special issue of Cardiovascular Research devoted to vascular 
inflammation edited by Markus Sperandio, Alexander Zarbock, and Klaus Ley 
includes a series of authoritative and detailed contributions, most of which speak to 
the functions of leukocytes and other blood cells in host defenses and disease. To 
place the individual articles into a broader context, the Figure attempts to integrate 
the roles of two major classes of leukocytes, the granulocyte and the 
monocyte/macrophage, into a temporal and spatial framework. While grossly 
oversimplified, the Figure depicts the role of the neutrophil as a mediator of acute 
inflammation that plays out over hours. In juxtaposition, mononuclear phagocytes, 
in the cardiovascular system and also other chronically diseased tissues (consider a 
granuloma in a tuberculous lung), persist in tissue spaces for days to years.  
Despite the vast differences in the timescales with which these leukocytes do their 
jobs, their recruitment and migration share many common themes. Yet, the fate of 
these different leukocyte classes varies considerably (Figure). Although 
polymorphonuclear leukocytes and monocyte/macrophages generally receive the 
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lion’s share of attention, other leukocyte classes also participate in host defenses 
and disease including mast cells, basophils, and eosinophils. Although tradition 
views the platelet as a “thrombocyte”, we now recognize platelets as active 
participants and amplifiers of local inflammatory responses. Platelets often 
associate with leukocytes, as discussed in the contribution by Rossaint and 
Zarbock in this compendium.  
Beyond the classification of different leukocyte lineages, the last decade has 
witnessed an explosion in understanding the heterogeneity of leukocytes within a 
given group.3 4 Virtually every leukocyte family includes various sub-types that 
subserve distinct functions and respond to and elaborate different, but often 
overlapping, patterns of mediators.  
While the traditional view of leukocyte participation in inflammation 
portrays them as phlogistic proagonists, some leukocyte sub-types appear to quell 
or moderate inflammation. Examples of such leukocytes that can limit 
inflammation or promote repair include Th2 lymphocytes, regulatory T cells (Treg) 
M2 macrophages, and Ly6clo monocytes. While some of the muting of 
inflammation mediated by certain leukocyte sub-types derives from the production 
of anti-inflammatory mediators such as IL-10 or transforming growth factor beta, 
recognition has increased that specific pathways of inflammation resolution, 
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distinct from anti-inflammatory mediators, usually involving lipids, can help limit 
inflammatory responses. 5, 6 
The translational challenge of inflammation in cardiovascular diseases 
Recent advances in leukocyte biology such as those described in the articles 
herein have unquestionably provided key new insights into pathophysiologic 
mechanisms. Our community’s reports of experimental results in this field often 
end with a promissory note regarding translation. Yet, a gap yawns between the 
elegant scientific findings such as those reported in the collection of articles in this 
issue, and the reduction to practice. Where do we stand in targeting inflammation 
in cardiovascular disease? (Table)  Despite the indubitable involvement of 
leukocyte recruitment in ischemia-reperfusion injury, scant therapeutic success has 
emerged from decades of attempts to target leukocyte recruitment in this context. 
The non-steroidal anti-inflammatory agents, in particular the cyclooxygenase-2 
selective members of this drug class, do not improve cardiovascular outcomes, 
rather to the contrary. The non-selective NSAIDS cause slight degrees of 
hypertension, which over time may wreak ravages in the cardiovascular system. 
The COX-2 selective inhibitors may tip the balance of prostanoid production 
towards excessive pro-aggregatory and vasoconstrictor prostaglandins. 
Glucocorticosteroids have potent and widespread anti-inflammatory effects, but 
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their use entails numerous undesired actions that could augment cardiovascular 
risk including hypertension, insulin insensitivity, and obesity. Aspirin provides 
protection against a second heart attack, and in some populations, stroke. But the 
doses of aspirin that exert beneficial cardiovascular actions fall far below the doses 
required for a true anti-inflammatory effect. By impeding platelet activation, 
however, even “cardioprotective” doses of aspirin may exert an indirect anti-
inflammatory action, a conjecture that requires further investigation.  
On the more positive side of the balance sheet, the statin class of 
hydroxymethylglutaryl co-enzyme A inhibitors resoundingly reduces 
cardiovascular event rates, but the extent to which they do so by anti-inflammatory 
functions distinct from lowering of low-density lipoprotein cholesterol remains 
controversial. A small study showed an impressive reduction in cardiovascular 
events with treatment with colchicine, an agent that interferes with leukocyte 
functions.7 This concept requires rigorous evaluation in a larger double-blind 
clinical trial. Methotrexate in low doses on a weekly dosing regimen has 
revolutionized the treatment of rheumatoid arthritis. A large clinical trial currently 
underway will evaluate its ability to reduce recurrent cardiovascular events in 
individuals at high risk.8 Another trial targets p38 MAP kinase, a key participant in 
the control of inflammation, in secondary prevention of atherosclerotic events.9 
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Anti-cytokine treatment has also proven highly beneficial in some inflammatory 
diseases such as rheumatoid arthritis. Yet, the anti-tumor necrosis factor antibodies 
associated with a signal for worsened outcome when studied in large clinical trials 
for heart failure. A large-scale clinical trial currently underway tests whether a 
monoclonal antibody that targets interleukin-1-beta might improve outcomes in 
survivors of myocardial infarction with persistent inflammation (despite 
contemporary standard of care treatment), as gauged by increased levels of the 
inflammatory biomarker C-reactive protein.10  
In sum, while inflammatory pathways such as those discussed in this series 
of articles remain enticing targets for therapeutic intervention, the promise remains 
unfulfilled. Given the redundancy of inflammatory pathways, targeting any one 
mediator may not suffice to limit cardiovascular inflammation in a meaningful 
way. On the other hand, intervening in pathways that participate in host defense 
runs the risk of impairing tumor surveillance or the ability of the host to combat 
infection. Thus, application of the growing body of detailed mechanistic insight we 
are acquiring regarding pathways of cardiovascular inflammation, the therapeutic 
application will require finding the “sweet spot,” where we selectively target the 
pathological pathway without impairing host defenses. Expanding knowledge of 
the fundamental mechanisms of inflammation provides the necessary foundation in 
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this regard. The clinical translation of the scientific advances reported in this 
compendium will require considerable rigor and resources, yet remains a goal to 
which we must aspire. 
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Table: 
Status of Anti-Infammatory Agents in Atherothrombotic Disease 
 
Anti-inflammatory strategies less likely to improve cardiovascular outcomes: 
Corticosteroids 
Non-steroidal anti-inflammatory drugs 
Anti-TNF agents 
 
Anti-inflammatory strategies that might improve cardiovascular outcomes: 
Colchicine - LoDoCo trial 7, PROBE design, n=532 
 
Anti-inflammatory strategies under evaluation in cardiovascular outcome 
trials: 
Methotrexate (low dose weekly) – CIRT 8, RCT, n=7,000 (enrolling) 
Anti-Interleukin-1 beta (canakinumab) – CANTOS 10, RCT, n= 10,060 (enrolled) 
p38 MAP kinase inhibitor (losmapimod) – LATITUDE/TIMI-60 9, RCT, n=25500, 
(enrolling) 
________________________ 
TNF: tumor necrosis factor 
PROBE: prospective randomized open blinded end-point 
RCT: randomized clinical trial 
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Panel a shows a simplified "lifecycle" of neutrophil responding to an acute 
inflammatory or injurious stimulus. The role of the neutrophil typically plays out in 
a matter of hours. The neutrophil can exercises functions intravascularly, in 
interstitial spaces, in walled – off collections (abscesses), or within the parenchyma 
of a tissue. After recruitment and activation, neutrophils release many mediators, in 
the context of cardiovascular disease notably reactive oxygen species including 
hypochlorous acid (HOCl) produced by myeloperoxidase (MPO.) The activated 
granulocyte can elaborate multiple lipid mediators of inflammation. In addition 
neutrophil granules contain proteolytic enzymes including neutrophil elastase 
(NE), cathepsin G (CatG), and proteinase 3 (Pr3.) The fates of this short-lived 
inflammatory cell includes classical apoptosis. The apoptotic cells and debris can 
be cleared by efferocytosis. In addition, the membrane of neutrophils and 
fragment, the histones of chromatin can undergo modification by deaminating 
enzymes that free DNA to spew forth into the extracellular space forming 
neutrophil extracellular traps (NETs), a process known as "NETosis." 
 
Panel b shows a simplified life history of a mononuclear phagocyte. 
Monocytes recruited into tissues mature into macrophages. These cells exert 
phagocytic activity, and also elaborate a myriad of mediators of inflammation. The 
macrophage can replicate within tissues or die, including by apoptosis. 
Mononuclear phagocytes may also emigrate into the lymph or blood. These 
processes generally play out over days or even years. 
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